MedTrace Logo

Does Sildenafil Improve Endothelial Dysfunction in Rheumatoid Arthritis?

NCT02908490 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2021-08-13

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether sildenafil improves parameters of vascular function and blood markers involved in development of heart disease in patients with rheumatoid arthritis.

Conditions

Interventions

DRUG

Sildenafil

Sildenafil 50 mg once daily

OTHER

Placebo

Placebo once daily with same size, shape, color, and texture as Sildenafil 50 mg pill

Sponsors & Collaborators

  • Kimberly Liang

    lead OTHER

Principal Investigators

  • Kimberly P Liang, MD · University of Pittsburgh

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-01
Primary Completion
2020-06-04
Completion
2020-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02908490 on ClinicalTrials.gov